[Skip to Content]
[Skip to Content Landing]

Talking to Your Patients About Breast Screening

Learning Objectives
1. Summarize the differences between data derived from randomized controlled trials, prospective studies, and modeling studies, and how data from each should be appropriately factored into breast cancer screening recommendations to patients
2. Describe the risks and benefits associated with modern breast cancer screening techniques
3. Explain methods used to convey accurate information to patients to promote informed shared decision-making regarding breast cancer screening
4. Recognize the impact current racial, ethnic and regional disparities have on breast cancer screening trends
1 Credit CME

Identify and assess reliable breast screening and outcomes data, discern actual breast cancer screening risks vs. benefits, and explain to patients when to be screened to avoid unnecessary death and treatment due to late or delayed breast cancer detection.

Sign in to take quiz and track your certificates

Module not playing? Click here

Activity Information

Credit Designation Statement: The American College of Radiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Radiology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACR Disclosure Policy: In compliance with ACCME requirements and guidelines, the ACR has developed a policy for disclosure and review of potential conflicts of interest, and a method for resolution if a conflict does exist. The ACR maintains a tradition of scientific integrity and objectivity in its educational activities. In order to preserve these values and ensure its educational activities are independent and free of commercial bias, all individuals, including planners, presenters, moderators and evaluators, participating in an ACR educational activity, or an activity jointly provided by the ACR must disclose all relevant financial relationships with any commercial interest.

The following planners and managers have no financial relationships to disclose:

Kelly Biggs, MD, Diane Dunne, Shawn Farley, Nazish Khaliq, Alexis LaCount, Deborah Monticciolo, MD, Dana Smetherman, MD

REFERENCES
1.
Tabár  L, Vitak  B, Chen  TH-H, Yen  AM-F, Cohen  A, Tot  T,  et al Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades.  Radiology. 2011;260(3):658–63.Google Scholar
2.
Broeders  M, Moss  S, Nyström  L, Njor  S, Jonsson  H, Paap  E,  et al The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies.  Journal of Medical Screening. 2012;19(1_suppl):14–25Google Scholar
3.
Coldman  A, Phillips  N, Wilson  C, Decker  K, Chiarelli  AM, Brisson  J,  et al Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer.  JNCI Journal of the National Cancer Institute. 2014;106(11):dju261-dju.Google Scholar
4.
Monticciolo  DL, Newell  MS, Hendrick  RE, Helvie  MA, Moy  L, Monsees  B, Kopans  DB, Eby  PR, Sickles  EA.  Breast cancer screening for average risk women: recommendations from the ACR commission on breast imaging.  J Am Coll Radiol. 2017 Sep;14(9):1137–1143. 10.1016/j.jacr.2017.06.001. Epub 2017 Jun 22.Google Scholar
5.
Arleo  EK, Hendrick  RE, Helvie  MA, Sickles  EA.  Comparison of recommendations for screening mammography using CISNET models.  Cancer. 2017;123(19):3673–3680. 10.1002/cncr.30842. Epub 2017 Aug 21.Google Scholar
6.
Helvie  MA, Chang  JT, Hendrick  RE, Banerjee  M.  Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer.  Cancer. 2014;120(17):2649–56Google Scholar
7.
Tabár  L, Yen  AM-F, Wu  WY-Y, Chen  SL-S, Chiu  SY-H, Fann  JC-Y,  et al Insights from the Breast Cancer Screening Trials: How Screening Affects the Natural History of Breast Cancer and Implications for Evaluating Service Screening Programs.  The Breast Journal. 2014;21(1):13–20Google Scholar
8.
Hellquist  BN, Duffy  SW, Abdsaleh  S, Björneld  L, Bordás  P, Tabár  L,  et al Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort.  Cancer. 2010;117(4):714–22.Google Scholar
9.
Puliti  D, Duffy  SW, Miccinesi  G, De Koning  H, Lynge  E, Zappa  M,  et al Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review.  Journal of Medical Screening. 2012;19(1_suppl):42–56Google Scholar
10.
Puliti  D, Bucchi  L, Mancini  S, Paci  E, Baracco  S, Campari  C,  et al Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy.  European Journal of Cancer. 2017;75:109–16Google Scholar
11.
Duffy  SW, Dibden  A, Michalopoulos  D, Offman  J, Parmar  D, Jenkins  J,  et al Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.  The Lancet Oncology. 2016;17(1):109–14.Google Scholar
12.
Saadatmand  S, Bretveld  R, Siesling  S, Tilanus-Linthorst  MMA.  Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients.  BMJ. 2015:h4901Google Scholar
13.
Lee  CS, Moy  L, Friedewald  SM, Sickles  EA, Monticciolo  DL.  Harmonizing breast cancer screening recommendations: metrics and accountability.  AJR Am J Roentgenol. 2017 Oct18 :1–5. 10.2214/AJR.17.18704. [Epub ahead of print]Google Scholar
14.
Friedewald  SM, Rafferty  EA, Rose  SL, Durand  MA, Plecha  DM, Greenberg  JS,  et al Breast Cancer Screening Using Tomosynthesis in Combination With Digital Mammography.  JAMA. 2014;311(24):2499.Google Scholar

Name Your Search

Save Search

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Topics
State Requirements